Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 6/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.31 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23743913 | 0.83 | HPGD (0.43) | HPGDSMN1; SMN2NOS3NOS2 | |
| SCHEMBL4082143 | 0.78 | RUNX1 (0.35) | HPGDSMN1; SMN2RUNX1LRRK2EGFR | |
| SCHEMBL14853181 | 0.75 | NOS2 (0.55) | HPGDSMN1; SMN2NOS3NOS2LRRK2 | |
| SCHEMBL4077989 | 0.72 | HPGD (0.49) | HPGDSMN1; SMN2LRRK2SSTR1SSTR4 | |
| SCHEMBL21669647 | 0.72 | HRH4 (0.33) | RUNX1LRRK2HRH4 | |
| SCHEMBL4072811 | 0.71 | ALDH1A1 (0.38) | RUNX1 | |
| SCHEMBL18935479 | 0.71 | F2R (0.38) | — | |
| SCHEMBL4077988 | 0.71 | HPGD (0.47) | HPGDSMN1; SMN2LRRK2SSTR1SSTR4 | |
| SCHEMBL5208254 | 0.70 | DRD1 (0.37) | HPGDSMN1; SMN2RUNX1SSTR1SSTR4 | |
| SCHEMBL4072808 | 0.70 | RUNX1 (0.37) | SMN1; SMN2RUNX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039943-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SLC10A1, SLCO1B3, SLC5A1 | HPGD 350/4885SMN1; SMN2 1100/4885RUNX1 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.